The U.S. Food and Drug Administration approved an expanded indication for Sanofi’s Toujeo (insulin glargine injection) for blood sugar control in adult and pediatric patients who are ages 6 years and older. The expanded indication approved by the FDA applies to both type 1 and 2 diabetes. Previously, Toujeo was U.S.-approved only for adults aged 18 years and older.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
Eli Lilly will add 100 jobs to the company’s manufacturing facilities at the Lilly Technology Center campus in Indianapolis.
AstraZeneca announced new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga (dapagliflozin) reduced the risk of the primary composite outcome of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.
Swiss company Vifor Pharma and Germany’s Evotec AG launched a joint venture to focus on the discovery and development of new therapies for kidney diseases.
Paris-based Sanofi presented data from the EDITION JUNIOR Phase III trial at the International Society for Pediatric and Adolescent Diabetes 45th Annual Conference held in Boston.
Novo Nordisk posted third-quarter 2019 operating profit a touch below expectations on weak insulin sales and impairments, but nudged up the company’s sales outlook on hopes for new type 2 diabetes and obesity drugs.
Sanofi expressed confidence for fourth-quarter 2019 and confirmed management’s objectives after posting lower third-quarter sales, hit by a fall in revenue at the company’s primary care business and a drop in vaccines.
Eli Lilly third-quarter 2019 sales missed Wall Street estimates as rebates limited revenue from the drug manufacturer’s top-selling diabetes medicine Trulicity, and shares fell about 4 percent.
AstraZeneca’s blockbuster drug Farxiga won U.S. approval as a treatment to reduce the chances of hospitalization for heart failure in adults with type 2 diabetes and other cardiovascular risks.